Lemon Balm/Melissa officinalis Cancer Research Results

MO, Lemon Balm/Melissa officinalis: Click to Expand ⟱
Features:

Lemon Balm / Melissa officinalis — A perennial medicinal herb of the Lamiaceae family used as leaf, tea, tincture, aqueous/hydroalcoholic extract, essential oil, or standardized polyphenol-rich extract. It is formally classified as a botanical/herbal medicinal product rather than a single-molecule drug. Common abbreviations include MO and, for extracts, MOE. Major constituents include rosmarinic acid (RA), caffeic-acid derivatives, flavonoids, triterpenoids, and volatile terpenes such as citronellal, citral, and geraniol; composition varies substantially with cultivar and extraction method. Cancer activity is predominantly preclinical, whereas human evidence is substantially stronger for anxiety/stress, sleep-related symptoms, and selected neurocognitive outcomes. Whole-herb effects should not be assumed to equal those of isolated rosmarinic acid.

Primary mechanisms (ranked):

  1. ROS-dependent apoptosis in susceptible cancer cells, with caspase-3/7 and PARP cleavage; antioxidant rescue experiments support a causal role for ROS in colorectal cancer models.
  2. Cell-cycle suppression, including G2/M arrest and inhibition of cyclin/CDK signaling.
  3. Suppression of migration and epithelial-mesenchymal transition, including increased E-cadherin and reduced N-cadherin in colorectal cancer models.
  4. Intrinsic and extrinsic apoptotic signaling, including BAX/BCL2 balance and FAS signaling in leukemia models.
  5. Cholinergic modulation, including acetylcholinesterase inhibition and interaction with muscarinic/nicotinic receptor systems.
  6. GABA transaminase inhibition, substantially associated with rosmarinic acid and potentially contributing to calming, anxiolytic, and sleep effects.
  7. Antioxidant and anti-inflammatory activity in non-cancer tissues; redox direction is therefore strongly context-dependent and differs from the pro-oxidant response reported in some cancer cells.
  8. Amyloid-β aggregation/deposition suppression, primarily supported by rosmarinic-acid-rich preparations and preclinical models rather than proven disease modification by ordinary lemon balm preparations.

Bioavailability / PK relevance: Lemon balm is a chemically heterogeneous botanical, so exposure depends strongly on extract composition and standardization. Rosmarinic acid has measurable systemic absorption but relatively low circulating concentrations compared with many mechanistic in-vitro experiments. After an extract supplying 500 mg rosmarinic acid, total serum rosmarinic acid peaked at approximately 162 nmol/L at about 1 hour in fasting subjects; food increased exposure and delayed peak concentration. These pharmacokinetic data argue against directly extrapolating high-concentration cellular effects to ordinary tea or supplement exposure.

In-vitro vs systemic exposure relevance: Many anticancer experiments used approximately 50–600 µg/mL of whole extract or fractions, including 120–346 µg/mL IC50 values and approximately 375–600 µg/mL exposures in colorectal models. Such whole-extract concentrations cannot be equated directly with measured circulating concentrations of rosmarinic acid after oral dosing and are unlikely to represent uniform systemic exposure to intact extract constituents. Anticancer findings should therefore be classified as mechanistically interesting but poorly translated pharmacokinetically. Local gastrointestinal exposure after oral administration may be more relevant to colorectal models than systemic exposure.

Clinical evidence status: Cancer: preclinical only, with in-vitro evidence and limited animal tumor evidence; no established anticancer indication or demonstrated clinical antitumor efficacy. Alzheimer’s disease/cognition: small and moderate-sized human randomized trials exist, but results are mixed; an early AD trial was positive, whereas later rosmarinic-acid-rich trials did not demonstrate consistent cognitive benefit. Anxiety/stress/sleep: multiple human trials and meta-analytic evidence support symptomatic activity, although formulations are heterogeneous. Lemon balm is marketed and regulated as an herbal/natural health product in multiple jurisdictions; EMA traditional-use indications include mild mental stress/sleep disturbance and mild gastrointestinal complaints, not cancer or Alzheimer’s disease treatment.

Melissa officinalis Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS-dependent apoptotic signaling ROS ↑; apoptosis ↑ Oxidative stress ↓ (context-dependent) G Selective pro-oxidant cytotoxicity in responsive cancer models Strongest mechanistic cancer finding. In HT-29 and T84 cells, antioxidant treatment prevented Melissa-induced apoptosis, supporting ROS as causal rather than merely associative. Redox direction is tissue- and preparation-dependent.
2 Caspase and PARP apoptosis axis Caspase-3 ↑; caspase-7 ↑; PARP cleavage ↑ ↔ (insufficient comparative evidence) G Execution of apoptotic cell death Demonstrated in colorectal models; increased caspase-7 and apoptotic markers were also observed in an experimental mammary tumor model.
3 Cell-cycle control G2/M arrest ↑; proliferation ↓ ↔ (insufficient comparative evidence) G Growth arrest Observed repeatedly in colorectal cancer cells. Mechanism varies somewhat with preparation and cell type.
4 Cyclin B1 CDC2 CDC25C axis Cyclin B1/CDC2 activity ↓; CDC25C ↓ ↔ G Blockade of mitotic entry Hot-water Melissa extract inhibited activation of the cyclin B1/CDC2 complex in HCT116 colorectal cancer cells.
5 CDK and cyclin growth signaling CDK2 ↓; CDK4 ↓; CDK6 ↓; cyclin D3 ↓; p21 ↑; p18 ↑ ↔ G Antiproliferative cell-cycle suppression Reported with ethanolic lemon balm extract in HT-29 and T84 colorectal cancer cells.
6 Mitochondrial apoptotic balance BAX ↑; BAX:BCL2 ratio ↑ ↔ G Intrinsic apoptosis ↑ Supported particularly by active dichloromethane fractions in Jurkat and K562 leukemia cells; should not automatically be generalized to all preparations.
7 FAS death-receptor signaling FAS ↑ ↔ G Extrinsic apoptosis ↑ Observed in leukemia models using active Melissa fractions and provides evidence for parallel intrinsic and extrinsic apoptotic pathways.
8 Epithelial-mesenchymal transition E-cadherin ↑; N-cadherin ↓; EMT ↓ ↔ G Migration and metastatic phenotype ↓ HCT116 migration was markedly suppressed by hot-water extract; mechanistic evidence supports reversal of EMT-associated marker expression.
9 Migration Migration ↓ ↔ G Reduced invasive phenotype Demonstrated in colorectal and other cancer-cell models but remains preclinical.
10 Tumor proliferation Ki-67 ↓; tumor growth ↓ ↔ G Reduced experimental mammary tumor growth A rat DMBA mammary-tumor study reported approximately 40% tumor-volume inhibition together with increased apoptosis and decreased Ki-67.
11 Clinical Translation Constraint High experimental concentrations; heterogeneous extracts Human tolerability generally favorable for studied oral preparations G Translation remains uncertain Most anticancer studies use tens to hundreds of µg/mL of extract. Human PK demonstrates only nanomolar circulating rosmarinic-acid concentrations after a very high 500 mg RA dose. No clinical anticancer efficacy has been established.

P: 0–30 min     R: 30 min–3 hr     G: >3 hr






Alzheimer’s disease relevance: Melissa officinalis warrants a separate AD/neurocognitive entry because human randomized trials exist in diagnosed Alzheimer’s disease as well as mild/subjective cognitive impairment. Evidence is nevertheless mixed. A four-month trial in 42 patients with mild-to-moderate AD reported significantly better ADAS-cog and CDR outcomes than placebo. A later 24-week randomized study of an extract providing 500 mg/day rosmarinic acid in 23 patients with mild AD found no significant cognitive benefit but did report improvement in neuropsychiatric symptoms. A much larger 96-week trial in 323 older adults with subjective or mild cognitive impairment found no significant benefit on the main cognitive outcomes. Thus, symptomatic/neuropsychiatric activity is more credible than established disease modification.

Mechanistic interpretation: The strongest AD-related mechanisms are cholinergic modulation, GABA-transaminase inhibition, and rosmarinic-acid-associated suppression of amyloid aggregation. AChE inhibition has been directly demonstrated in vitro, with rosmarinic-acid-related fractions among the most active. Melissa also interacts with muscarinic and nicotinic cholinergic systems. GABA-T inhibition is better regarded as a neurobehavioral mechanism relevant to anxiety, agitation, and sleep than as a central AD disease-modifying mechanism. Amyloid effects are promising but largely constituent-driven and preclinical.

Melissa officinalis Alzheimer’s Mechanisms

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Acetylcholinesterase AChE ↓ Acetylcholine availability potentially ↑ Direct in-vitro inhibition has been demonstrated; activity varies considerably with extraction method and phytochemical composition.
2 Cholinergic receptor signaling Muscarinic and nicotinic receptor interaction ↑ (context-dependent) Cholinergic neurotransmission modulation Human cortical receptor-binding experiments support direct interaction by selected Melissa extracts, but this is not equivalent to proven receptor agonism in vivo.
3 Amyloid-beta aggregation Aβ fibril formation and oligomerization ↓ Amyloidogenic burden potentially ↓ Predominantly rosmarinic-acid-driven and supported by biochemical and animal evidence; disease modification has not been confirmed clinically.
4 Amyloid deposition Aβ deposition ↓ (preclinical) Reduced experimental amyloid burden Most evidence derives from rosmarinic acid or RA-rich Melissa preparations rather than ordinary lemon balm tea.
5 GABA transaminase GABA-T ↓ GABAergic tone potentially ↑ Rosmarinic acid is an important active constituent. This mechanism is likely more relevant to calming, anxiety, sleep, and behavioral symptoms than to core AD pathology.
6 Oxidative stress Oxidative stress ↓ Neuroprotective antioxidant effect Consistent preclinical pharmacology, but direct evidence that this mechanism alters human AD progression is lacking.
7 Neuroinflammatory signaling Inflammatory signaling ↓ (model-dependent) Potential neuroprotection Supported primarily by preclinical work and general Melissa pharmacology rather than definitive AD clinical biomarker evidence.
8 Neuropsychiatric symptoms NPI-Q symptoms ↓ Potential symptomatic benefit A 24-week randomized AD trial found a significant between-group difference in neuropsychiatric symptoms despite no significant cognitive benefit.
9 Cognitive function ↔ / ↑ (trial-dependent) Mixed clinical effect An early AD RCT was positive, whereas later 24-week and 96-week trials did not show consistent cognitive improvement.
10 Clinical Translation Constraint Evidence mixed No established AD disease-modifying efficacy Extract composition, rosmarinic-acid content, dose, study population, and clinical endpoints vary substantially among trials.


Scientific Papers found: Click to Expand⟱
8582- GBE,  Cro,  Sage,  MO,    A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer’s disease and dementia
- Review, AD, NA
*NA↑, *cognitive↑, *eff↑, *BloodF↑, *MMP↝, *ROS↓, *SOD↑, *GSH↑, *AChE↓, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Mood?,
8610- MO,    Melissa officinalis extract induces apoptosis and inhibits proliferation in colon cancer cells through formation of reactive oxygen species
- in-vitro, CRC, HT-29 - in-vitro, Colon, T84
TumCP↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, CDKN2C/p18↑, P21↑, cl‑Casp3↑, cl‑Casp7↑, Apoptosis↑, ROS↑, eff↓,
8611- MO,    Antitumoral effects of Melissa officinalis on breast cancer in vitro and in vivo
- vitro+vivo, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
Casp7↑, Ki-67↓, TumVol↓,
8612- MO,  MTX,    Lemon Balm Attenuates Methotrexate-Induced Testicular Damage Through Modulation of Oxidative Stress and p-p38 MAPK Signaling
- in-vivo, Nor, NA
*ROS↓, *Inflam↓, *p‑p38↓,
8613- MO,    Unraveling the Effects of Melissa officinalis L. on Cognition and Sleep Quality: A Narrative Review
- Review, AD, NA
*Sleep↑, *Mood↑, *Synergy↑, *QoL↑, *cognitive↑, *ROS↓, *NRF2↑, *HO-1↑, *NF-kB↓, *TNF-α↓, *COX2/PTGS2↓, *MDA↓, *Catalase↑, *SOD↑, *BDNF↑, *Dose↝,
8614- MO,  RosA,    Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial
- Trial, AD, NA
*cognitive↑, *Dose↝,
8615- MO,    Melissa officinalis Extract Induces Apoptosis and Inhibits Migration in Human Colorectal Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29 - in-vitro, CRC, SW-620
AntiCan↑, TumCP↓, TumCCA↑, Casp↑, TumCMig↓, EMT↓, other↑,
8616- MO,  RosA,    Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L
- Study, AD, NA
*AChE↓, *Ingr↝,
8617- MO,    Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial
- Trial, AD, NA
*cognitive↑, *Mood↑, *Dose↝, *Dose?,
8618- MO,    Lemon Balm Extracts Prevent Breast Cancer Progression In Vitro and In Ovo on Chorioallantoic Membrane Assay
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
tumCV↓, selectivity?, Ingr↝, Dose↝, eff?, angioG↓, chemoPv↑,
8619- MO,  doxoR,    Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells
- vitro+vivo, BC, MCF7
*Dose↝, *cardioP↑, *ROS↓, *lipid-P↓, *antiOx↑, *Inflam↓, *NF-kB↓, *TNF-α↓, *COX2/PTGS2↓, *MPO↓, ChemoSen↑, *Dose↝, *AST↓, *CK/CK-MB↓, *SOD↑, Synergy↑, MDA↑, NO↑, GSH↓, ROS↑,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 1,   MDA↑, 1,   ROS↑, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp↑, 1,   cl‑Casp3↑, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   tumCV↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CDK6↓, 1,   CDKN2C/p18↑, 1,   cycD1/CCND1↓, 1,   Ki-67↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCP↓, 2,  

Migration(tgid=13) ⓘ

EMT↓, 1,   TumCMig↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   NO↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff?, 1,   eff↓, 1,   selectivity?, 1,   Synergy↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoPv↑, 1,   TumVol↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 4,   SOD↑, 3,  

Cell Death(tgid=5) ⓘ

p‑p38↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   Inflam↓, 2,   NF-kB↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BDNF↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose?, 1,   Dose↝, 10,   eff↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AST↓, 1,   BloodF↑, 1,   CK/CK-MB↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   cognitive↑, 4,   Mood?, 1,   Mood↑, 2,   QoL↑, 1,   Sleep↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 33

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:489  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page